Original articleCarbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII
Graphical abstract
A novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides have been synthesized and investigated as inhibitors of carbonic anhydrase isozymes hCA I, II, IX and XII. Some of them showed excellent hCA IX and XII inhibitory efficacy.
Introduction
The carbonic anhydrases (CAs, EC 4.2.1.1) [1], [2], [3], [4] constitute interesting targets for the design of pharmacological agents useful in the treatment or prevention of a variety of disorders such as glaucoma, acid-base disequilibria, epilepsy and other neuromuscular diseases, altitude sickness, edema, and obesity [5], [6]. A quite new and unexpected application of the CA inhibitors (CAIs) regards their potential use in the management (imaging and treatment) of hypoxic tumors [7], [8], [9], [10], [11], [12], [13], [14], since at least two CA isozymes of the 15 presently known in humans, that is CA IX and XII, are predominantly found in tumor cells and lack (or are present in very limited amount) in normal tissues [15], [16], [17], [18]. The potential use of CAIs as antitumor agents opens thus a new important research direction [19], [20].
Recently, we have reported on the strong inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with some S-substituted 4-chloro-5-or 6-methylbenzenesulfonamides I and II [21], [22], [23] (Chart 1). We also described the syntheses a number of 4-substituted 3-pyridinesulfonamides of type III (Chart 1), and their inhibitory activities against human isozymes hCA I, II, IX, XII and XIV [24]. Some of these compounds exhibited excellent hCA IX inhibitory efficacy, with inhibition constants of 4.6–12.0 nM, being much more effective as compared to the clinically used sulfonamides AAZ, MZA, EZA, DCP and IND (in clinical development drug). These findings prompted us to synthesize and investigate of the related 3-pyridinesulfonamides of type IV (Chart 1).
Section snippets
Chemistry
The previously described method was applied to the synthesis of 4-methoxy-3-pyridinesulfonamide 1 [24]. The synthesis of the target 1,4-dihydro-4-oxo-3-pyridinesulfonamides 2–15 were achieved with yields in the 59–97% range by a convenient one-step procedure starting from 4-methoxy-3-pyridinesulfonamide 1 and the appropriate activated aliphatic or aromatic halides in dry acetonitrile. The proposed mechanism leading to the formation of the products 2–15 is outlined in Scheme 1, Scheme 2. The
Conclusions
We have developed methods for the regioselective synthesis of 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides. The fourteen new sulfonamide have been assayed for the inhibition of four physiological relevant CA isozymes, such as CA I and II, and the tumor-associated isozymes CA IX and XII. Against the human isozyme hCA I the new sulfonamide showed inhibition constants in the range of 1.09–14.2 μM; against hCA II in the range 50.5–172 nM, against hCA IX in the range 5.2–96 nM, and against
Synthesis
The following instruments and parameters were used: melting points Bűchi 535 apparatus; IR spectra: KBr pellets, 400–4000 cm−1 Perkin Elmer 1600 FTIR spectrometer; 1H and 13C NMR: Varian Gemini 200 apparatus at 200 and 50 MHz, respectively; chemical shifts are expressed in parts per million (ppm) relative to TMS as internal standard. The results of elemental analyses for C, H and N were within ±0.4% of theoretical values. The starting 4-methoxy-3-pyridinesulfonamide 1 was prepared according to
Acknowledgments
This research was financed in part by a grant of the 6th Framework Programme of the European Union (DeZnIT project) and by a grant of the 7th FP of EU (Metoxia project) to CTS.
References (31)
- et al.
FEBS Lett.
(2004) - et al.
Bioorg. Med. Chem. Lett.
(2003) - et al.
Bioorg. Med. Chem. Lett.
(2004) - et al.
Trends Pharmacol. Sci.
(2006) - et al.
Bioorg. Med. Chem. Lett.
(2006) - et al.
Eur. J. Med. Chem.
(2010) - et al.
Tetrahedron Lett.
(1995) J. Biol. Med.
(1971)- et al.
Bioorg. Med. Chem. Lett.
(2005) Nat. Rev. Drug Discov.
(2008)
Expert Opin. Ther. Pat.
Carbonic anhydrase: catalytic and inhibition mechanisms, distribution and physiological roles
Curr. Chem. Caridiovasc. Hematol. Agents
J. Enzym. Inhibit. Med. Chem.
Expert Opin. Ther. Pat.
Cited by (26)
Bicyclic 6-6 Systems: Four Heteroatoms 1:3
2021, Comprehensive Heterocyclic Chemistry IVCarbonic anhydrase inhibitory properties of phenolic sulfonamides derived from dopamine related compounds
2017, Arabian Journal of ChemistryCitation Excerpt :The results obtained from Table 2 clearly show that the physiologically dominant cytosolic isozymes hCA I, and II were effectively inhibited by sulfonamide compounds 1–4. The reason for this is that both cytosolic isoenzymes have a high sequence of amino acid homology within their active sites (Xue et al., 1993; Brzozowski et al., 2012). Sulfonamides 1–4 have one aromatic ring and –OH groups.
Structure determination, synthesis, and biological evaluation of a metabolite of the selective α<inf>1D</inf>adrenoceptor antagonist TAK-259
2016, TetrahedronCitation Excerpt :In the absence of LiBr, nucleophilic substitution of 12 to 9a proceeds at the 2-amino group (route G) along with the nitrogen atom of the pyridine ring (route F) to produce 13 and 2a (Step 2, i)). In contrast, in the presence of LiBr, demethylation of 12 at the 4-position and subsequent alkylation between 12 and 9a occurs in a concerted manner to produce 4-pyridone 2a dominantly (Step 2, ii)).16,17 The binding affinities of metabolite 2a toward the α1 adrenoceptor subtypes were evaluated using a binding assay.
Synthesis of a new series of N<sup>4</sup>-substituted 4-(2-aminoethyl) benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes i and II and transmembrane tumor-associated isozymes IX and XII
2014, European Journal of Medicinal ChemistryCitation Excerpt :We have reported on the strong inhibition of human cytosolic isozymes CA I and II and tumor-associated isozymes IX and XII with some 4-chloro-5-methyl-2-(R-thio)benzenesulfonamides of type II [15–17] (Fig. 1). We also described the synthesis a number of pyridine-3-sulfonamides of types III and IV [18–20] and V [21,22] and inhibitory activities against isozymes hCA I, II, IX, XII and XIV [10,11,23]. Numerous of these compounds exhibit excellent hCA IX inhibitory efficacy with inhibition constants 4.6–12.0 nM, being thus much more effective as compared to the clinically used sulfonamides AAZ, MZA, EZA, DCP and IND (KI = 24–50 nM).
Substituted benzene sulfonamides incorporating 1,3,5-triazinyl moieties potently inhibit human carbonic anhydrases II, IX and XII
2014, Bioorganic and Medicinal Chemistry Letters